PE44799A1 - Antagonistas del receptor de vitronectina - Google Patents
Antagonistas del receptor de vitronectinaInfo
- Publication number
- PE44799A1 PE44799A1 PE1998000013A PE00001398A PE44799A1 PE 44799 A1 PE44799 A1 PE 44799A1 PE 1998000013 A PE1998000013 A PE 1998000013A PE 00001398 A PE00001398 A PE 00001398A PE 44799 A1 PE44799 A1 PE 44799A1
- Authority
- PE
- Peru
- Prior art keywords
- cyclohepten
- dibenzo
- dihydro
- acetic
- acid
- Prior art date
Links
- 102100022337 Integrin alpha-V Human genes 0.000 title abstract 2
- 108010048673 Vitronectin Receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 abstract 2
- IFFLKGMDBKQMAH-UHFFFAOYSA-N 2,4-diaminopyridine Chemical compound NC1=CC=NC(N)=C1 IFFLKGMDBKQMAH-UHFFFAOYSA-N 0.000 abstract 1
- ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE REFIEREN A LOS C0MPUESTOS: ACIDO (�)-10,11-DIHIDRO-3-[3-(4-AMINO-2-PIRIDILAMINO)-1-PROPILOXI]-5H-DIBENZO[a,d]CICLOHEPTEN-10-ACETICO; ACIDO (�)-10,11-DIHIDRO-3-[2-[6-(ETILAMINO)-2-PIRIDIL]-1-ETOXI]-5H-DIBENZO[a,d]CICLOHEPTEN-10-ACETICO; ACIDO (�)-10,11-DIHIDRO-3-[3-(4-METIL-2-PIRIDILAMINO)-1-PROPILOXI]-5H-DIBENZO[a,d]CICLOHEPTEN-10-ACETICO Y TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE LOS COMPUESTOS INTERMEDIOS (I) Y (II), Y A LOS COMPUESTOS INTERMEDIOS. LOS TRES COMPUESTOS ANTERIORMENTE MENCIONADOS ACTUAN COMO INHIBIDORES SELECTIVOS DEL RECEPTOR DE VITRONECTINA (Ov�3 y Ov�5), SIENDO UTILES EN EL TRATAMIENTO DE LA OSTEOPOROSIS, RESTENOSIS, ENTRE OTROS, ADEMAS SON UTILES EN EL TRATAMIENTO DEL CANCER, SOLOS O ACOMPANADOS CON UN AGENTE ANTINEOPLASICO TAL COMO TOPOTECANO o CISPLATIN
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3402697P | 1997-01-08 | 1997-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE44799A1 true PE44799A1 (es) | 1999-06-10 |
Family
ID=21873846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1998000013A PE44799A1 (es) | 1997-01-08 | 1998-01-07 | Antagonistas del receptor de vitronectina |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6069158A (es) |
| EP (1) | EP0977735B1 (es) |
| JP (1) | JP2001508067A (es) |
| KR (1) | KR20000069941A (es) |
| CN (1) | CN1249745A (es) |
| AP (1) | AP9901597A0 (es) |
| AR (1) | AR010873A1 (es) |
| AT (1) | ATE235467T1 (es) |
| AU (1) | AU729641B2 (es) |
| BG (1) | BG103548A (es) |
| BR (1) | BR9806852A (es) |
| CA (1) | CA2276738A1 (es) |
| CO (1) | CO4920232A1 (es) |
| DE (1) | DE69812602T2 (es) |
| DZ (1) | DZ2395A1 (es) |
| EA (1) | EA199900630A1 (es) |
| ES (1) | ES2196534T3 (es) |
| HU (1) | HUP0001945A3 (es) |
| ID (1) | ID23168A (es) |
| IL (1) | IL130760A0 (es) |
| MA (1) | MA26462A1 (es) |
| NO (1) | NO993350L (es) |
| NZ (1) | NZ336560A (es) |
| OA (1) | OA11076A (es) |
| PE (1) | PE44799A1 (es) |
| PL (1) | PL334499A1 (es) |
| SK (1) | SK92799A3 (es) |
| TR (1) | TR199901575T2 (es) |
| WO (1) | WO1998030542A1 (es) |
| ZA (1) | ZA9896B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011626A1 (en) * | 1997-09-04 | 1999-03-11 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| US6576643B2 (en) | 1997-09-19 | 2003-06-10 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| PE122699A1 (es) * | 1997-09-19 | 2000-02-12 | Smithkline Beecham Corp | Antagonistas de receptores de vitronectina |
| WO1999052872A1 (en) | 1998-04-09 | 1999-10-21 | Meiji Seika Kaisha, Ltd. | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS |
| JP4240424B2 (ja) * | 1998-10-23 | 2009-03-18 | エルジー ディスプレイ カンパニー リミテッド | エッチング剤及びこれを用いた電子機器用基板の製造方法 |
| US6339083B1 (en) | 1998-12-14 | 2002-01-15 | Bayer Aktiengesellschaft | Multiheterocyclic pharmAceuticals |
| AU747503B2 (en) | 1999-02-03 | 2002-05-16 | Merck & Co., Inc. | Benzazepine derivatives as alpha-V integrin receptor antagonists |
| DE19916837A1 (de) * | 1999-04-14 | 2000-10-19 | Merck Patent Gmbh | Dibenzoazulenderivate |
| AU6316900A (en) | 1999-08-05 | 2001-03-05 | Meiji Seika Kaisha Ltd. | Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alphavbeta3antagonism |
| DE19936780A1 (de) | 1999-08-09 | 2001-02-15 | Basf Ag | Neue Antagonisten von Integrinrezeptoren |
| FR2806082B1 (fr) * | 2000-03-07 | 2002-05-17 | Adir | Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU2002239435B2 (en) * | 2000-10-24 | 2005-10-27 | Merck & Co., Inc. | Dibenzoxazepine alpha v integrin receptor antagonist |
| EP1381384B1 (en) | 2001-04-24 | 2011-05-25 | Merck Patent GmbH | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha |
| EP1443963B1 (en) | 2001-10-22 | 2014-05-21 | The Scripps Research Institute | Antibody targeting compounds |
| GB0215867D0 (en) * | 2002-07-09 | 2002-08-14 | Glaxosmithkline Spa | Novel method and compounds |
| EP2394662B1 (en) * | 2004-04-02 | 2018-03-21 | The Regents of The University of California | Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin |
| AU2012216372B2 (en) * | 2004-04-02 | 2015-01-22 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| ATE443718T1 (de) | 2005-05-31 | 2009-10-15 | Ralf Jochem | Therapeutsche zusammensetzung zur vorbeugung und bekämpfung von knochenmetastasen |
| JP2009512443A (ja) * | 2005-10-20 | 2009-03-26 | ザ スクリップス リサーチ インスチチュート | 免疫染色及び免疫標的化のためのＦｃ標識化 |
| ES2521679T3 (es) | 2006-01-18 | 2014-11-13 | Merck Patent Gmbh | Terapia específica usando ligandos de integrinas para el tratamiento del cáncer |
| WO2008087025A2 (en) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Specific therapy and medicament using integrin ligands for treating cancer |
| KR101595238B1 (ko) | 2007-12-21 | 2016-02-18 | 리간드 파마슈티칼스 인코포레이티드 | 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도 |
| EP2395992A2 (en) | 2009-02-10 | 2011-12-21 | The Scripps Research Institute | Chemically programmed vaccination |
| NZ597339A (en) | 2009-05-25 | 2013-10-25 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
| US10087252B2 (en) | 2009-07-24 | 2018-10-02 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with αvβ5 integrin |
| KR20160147007A (ko) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체 |
| CA3133929A1 (en) | 2019-04-19 | 2020-10-22 | Lin Zhi | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794424A (fr) * | 1972-01-24 | 1973-07-23 | Science Union & Cie | Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament |
| US3906032A (en) * | 1972-11-10 | 1975-09-16 | Squibb & Sons Inc | Dihydroxy-tetrahydronaphthyoxyisobutyric acids and alkyl esters and salts thereof |
| IT1222986B (it) * | 1987-10-23 | 1990-09-12 | Texcontor Ets | Derivati dell'efedrina esterificata aventi attivita' antiulcera prolungata nel tempo |
| US4994463A (en) * | 1987-12-14 | 1991-02-19 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic thromboxane A2 antagonists |
| WO1997001540A1 (en) * | 1995-06-29 | 1997-01-16 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| BR9612381A (pt) * | 1995-12-29 | 1999-07-13 | Smithkline Beecham Corp | Antagonistas receptores vitronectina |
| EP1000031A4 (en) * | 1997-07-25 | 2001-08-16 | Smithkline Beecham Corp | VITRONECTIN RECEPTOR ANTAGONISTS |
| PE122699A1 (es) * | 1997-09-19 | 2000-02-12 | Smithkline Beecham Corp | Antagonistas de receptores de vitronectina |
-
1997
- 1997-12-30 CO CO97075531A patent/CO4920232A1/es unknown
-
1998
- 1998-01-02 MA MA24917A patent/MA26462A1/fr unknown
- 1998-01-05 AR ARP980100031A patent/AR010873A1/es not_active Application Discontinuation
- 1998-01-07 ZA ZA9896A patent/ZA9896B/xx unknown
- 1998-01-07 PE PE1998000013A patent/PE44799A1/es not_active Application Discontinuation
- 1998-01-08 BR BR9806852-0A patent/BR9806852A/pt not_active Application Discontinuation
- 1998-01-08 HU HU0001945A patent/HUP0001945A3/hu unknown
- 1998-01-08 IL IL13076098A patent/IL130760A0/xx unknown
- 1998-01-08 JP JP53117598A patent/JP2001508067A/ja active Pending
- 1998-01-08 DE DE69812602T patent/DE69812602T2/de not_active Expired - Lifetime
- 1998-01-08 EA EA199900630A patent/EA199900630A1/ru unknown
- 1998-01-08 AP APAP/P/1999/001597A patent/AP9901597A0/en unknown
- 1998-01-08 ID IDW990650D patent/ID23168A/id unknown
- 1998-01-08 AT AT98902477T patent/ATE235467T1/de not_active IP Right Cessation
- 1998-01-08 ES ES98902477T patent/ES2196534T3/es not_active Expired - Lifetime
- 1998-01-08 WO PCT/US1998/000490 patent/WO1998030542A1/en not_active Ceased
- 1998-01-08 SK SK927-99A patent/SK92799A3/sk unknown
- 1998-01-08 CA CA002276738A patent/CA2276738A1/en not_active Abandoned
- 1998-01-08 TR TR1999/01575T patent/TR199901575T2/xx unknown
- 1998-01-08 CN CN98802983A patent/CN1249745A/zh active Pending
- 1998-01-08 KR KR1019997006154A patent/KR20000069941A/ko not_active Ceased
- 1998-01-08 US US09/331,914 patent/US6069158A/en not_active Expired - Lifetime
- 1998-01-08 PL PL98334499A patent/PL334499A1/xx unknown
- 1998-01-08 EP EP98902477A patent/EP0977735B1/en not_active Expired - Lifetime
- 1998-01-08 NZ NZ336560A patent/NZ336560A/xx unknown
- 1998-01-08 AU AU59127/98A patent/AU729641B2/en not_active Ceased
- 1998-06-07 DZ DZ980005A patent/DZ2395A1/xx active
-
1999
- 1999-07-01 BG BG103548A patent/BG103548A/xx unknown
- 1999-07-07 NO NO993350A patent/NO993350L/no not_active Application Discontinuation
- 1999-07-08 OA OA9900155A patent/OA11076A/en unknown
-
2000
- 2000-04-18 US US09/551,743 patent/US6191304B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE44799A1 (es) | Antagonistas del receptor de vitronectina | |
| NZ522326A (en) | Adenosine A2A receptor antagonists | |
| ATE249213T1 (de) | Pentafluorobenzensulfonamiden und analoge | |
| CA2366702A1 (en) | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents | |
| ES2167377T3 (es) | Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos. | |
| TR200201001T2 (tr) | Pürin türevleri | |
| TW200626572A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| BRPI0011856B8 (pt) | agonistas de receptor a2a de n-pirazol | |
| BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
| AR035711A1 (es) | Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas | |
| BR0111016A (pt) | Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos | |
| MY137535A (en) | New pyrrolidinium derivatives | |
| TW200518753A (en) | Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents | |
| TW200626148A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| TNSN05189A1 (en) | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis | |
| TR200200985T2 (tr) | Pürin türevleri | |
| EP0361936A3 (en) | Lasing compositions and methods for using the same | |
| TW200626592A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| ES2010226A6 (es) | Un procedimiento para producir una preparacion farmaceutica estable que contiene un factor estimulante de colonias de granulocitos | |
| PT1093819E (pt) | Compostos e composicoes para fornecimento de agentes activos | |
| EE9900539A (et) | Uued ühendid | |
| WO2003022216A3 (en) | Biaryl substituted purine derivatives as potent antiproliferative agents | |
| ATE309007T1 (de) | Transplantate für die wiederherstellung von osteochondralen schäden | |
| ATE450265T1 (de) | Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält | |
| AR026064A1 (es) | Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |